Maxcyte, Inc.
MXCT- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001287098
In the last 90 days, Maxcyte, Inc. insiders filed 1 open-market purchase and 0 sales; 118 institutions reported holding it in 13F filings for Q3 2026, worth $72.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:13 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $44.6M (135.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 6, 2023 | Jan 24, 2022 |
| Revenue | $33.0M | $38.6M | $41.3M | $44.3M | $33.9M |
| Cost of revenue | $6.22M | $7.10M | $4.74M | $5.10M | $3.65M |
| Gross profit | $26.8M | $31.5M | $36.5M | $39.2M | $30.2M |
| Operating expenses | $78.7M | $82.7M | $84.8M | $66.5M | $48.4M |
| Research and development | $20.8M | $22.2M | $23.8M | $19.5M | $15.4M |
| Selling, general and administrative | $28.1M | $29.7M | $30.1M | $25.8M | $18.7M |
| Operating income | -$51.9M | -$51.2M | -$48.3M | -$27.4M | -$18.2M |
| Interest expense | – | – | – | – | $5.40K |
| Income tax | – | – | – | – | $0 |
| Net income | -$44.6M | -$41.1M | -$37.9M | -$23.6M | -$19.1M |
| EPS, basic | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 |
| EPS, diluted | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 |
| Weighted shares, basic | 106.4M | 104.8M | 103.3M | 101.7M | 90.6M |
| Weighted shares, diluted | 106.4M | 104.8M | 103.3M | 101.7M | 90.6M |
| Margins and growth | |||||
| Gross margin | 81.2% | 81.6% | 88.5% | 88.5% | 89.2% |
| Operating margin | -157.1% | -132.5% | -117.0% | -61.8% | -53.7% |
| Net margin | -135.1% | -106.3% | -91.8% | -53.3% | -56.3% |
| Revenue growth, year over year | −14.5% | −6.4% | −6.7% | +30.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 6, 2023 | Jan 24, 2022 |
| Cash and equivalents | $20.1M | $27.9M | $46.5M | $11.1M | $47.8M |
| Short-term investments | $83.0M | $126.6M | $121.8M | $216.3M | $207.3M |
| Accounts receivable | $3.50M | $4.68M | $5.78M | $11.7M | $6.88M |
| Inventory | $7.55M | $8.91M | $12.2M | $8.58M | $5.20M |
| Total current assets | $118.4M | $171.7M | $190.2M | $252.3M | $270.4M |
| Property, plant and equipment | $17.5M | $19.7M | $23.5M | $23.7M | $7.68M |
| Intangible assets | $650.0K | – | – | – | – |
| Total assets | $202.5M | $239.5M | $268.3M | $286.7M | $284.1M |
| Accounts payable | $1.40M | $1.36M | $743.0K | $531.8K | $1.82M |
| Total current liabilities | $14.3M | $15.8M | $17.9M | $15.4M | $15.6M |
| Total liabilities | $31.0M | $33.2M | $36.1M | $32.7M | $21.2M |
| Shareholders' equity | $171.5M | $206.3M | $232.2M | $254.0M | $262.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Mar 6, 2023 | Jan 24, 2022 |
| Operating cash flow | -$34.4M | -$27.6M | -$21.7M | -$14.8M | -$10.7M |
| Capital expenditures | $1.77M | $1.65M | $3.70M | $18.5M | $3.83M |
| Free cash flow | -$36.2M | -$29.3M | -$25.4M | -$33.3M | -$14.5M |
| Depreciation and amortization | $4.34M | $4.32M | $4.17M | $2.70M | $1.42M |
| Stock-based compensation | $9.21M | $13.1M | $14.0M | $11.8M | $7.96M |
| Investing cash flow | $25.9M | $6.93M | $55.0M | -$24.8M | -$195.0M |
| Financing cash flow | $656.0K | $2.06M | $2.14M | $2.89M | $234.7M |
| Net change in cash | -$7.82M | -$18.6M | $35.4M | -$36.7M | $29.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 27.9% | 33.9% | 33.9% | 26.6% | 23.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 103.3M | −3.2% | SEC |
| Aug 7, 2026 | 103.2M | −3.2% | SEC |
| May 7, 2026 | 107.1M | +0.8% | SEC |
| Mar 17, 2026 | 106.9M | +0.8% | SEC |
| Nov 7, 2025 | 106.7M | +1.1% | SEC |
| Aug 1, 2025 | 106.6M | +1.4% | SEC |
| May 1, 2025 | 106.3M | +1.7% | SEC |
| Mar 7, 2025 | 106.0M | +1.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.